Head-To-Head Contrast: Pulmonx (NASDAQ:LUNG) vs. Biotricity (OTCMKTS:BTCY)

Pulmonx (NASDAQ:LUNG) and Biotricity (OTCMKTS:BTCY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Valuation & Earnings

This table compares Pulmonx and Biotricity”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50 million	0.83	-$54.00 million	($1.33)	-1.37
Biotricity	$13.79 million	0.49	-$8.42 million	($0.16)	-1.47

Biotricity has lower revenue, but higher earnings than Pulmonx. Biotricity is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Pulmonx has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.

Profitability

This table compares Pulmonx and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	-59.67%	-78.35%	-37.14%
Biotricity	-25.99%	N/A	-67.82%

Institutional and Insider Ownership

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by insiders. Comparatively, 10.1% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pulmonx and Biotricity, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1	3	4	0	2.38
Biotricity	0	0	0	0	0.00

Pulmonx currently has a consensus target price of $5.38, indicating a potential upside of 195.53%. Given Pulmonx’s stronger consensus rating and higher possible upside, equities analysts plainly believe Pulmonx is more favorable than Biotricity.

Summary

Pulmonx beats Biotricity on 8 of the 14 factors compared between the two stocks.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.